GLP-1 Complexity And Rising Costs Will Challenge Virtual Care Scale Yet Eventually Support Returns

Catalysts

About Omada Health

Omada Health provides virtual care programs that help people manage chronic conditions such as cardiometabolic disease and musculoskeletal issues on behalf of employers and health plans.

What are the underlying business or industry changes driving this perspective?

• Although payer interest in GLP-1 obesity drugs is creating new demand for Omada's GLP-1 Care Track and upcoming prescribing capability, the need to invest in engineering, product and commercial build-out for this offering could weigh on operating expenses and delay progress toward higher net margins and adjusted earnings.
• Although employers and health plans are looking for partners that can coordinate care for obesity medications, the growing complexity of oral and injectable options across multiple indications may stretch Omada's care teams and technology platform. This could pressure gross margin if support costs rise faster than GLP-1 related revenue.
• While chronic cardiometabolic conditions affect more than 150 million Americans and Omada is seeing member growth tied to multi-condition adoption, enterprise selling cycles of 6 to 18 months and customers reconsidering GLP-1 coverage policies can slow the conversion of pipeline into new memberships. This may affect the pace of revenue growth and earnings visibility.
• Although Omada's AI tools like OmadaSpark and Meal Map are associated with higher engagement and more efficient care delivery, continued spending on AI capabilities to support both members and care teams could absorb much of the current operating leverage. This may limit near term improvement in adjusted EBITDA margins.
• While research publications and real world data on joint and muscle health and weight maintenance after GLP-1 discontinuation help Omada appeal to employers focused on medical cost savings, translating these outcomes into consistently higher pricing or broader benefit coverage is not guaranteed. This could cap average revenue per member and slow expansion in gross profit and net income.

Assumptions

This narrative explores a more pessimistic perspective on Omada Health compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Omada Health's revenue will grow by 26.6% annually over the next 3 years.
• The bearish analysts are not forecasting that Omada Health will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Omada Health's profit margin will increase from -11.3% to the average US Healthcare industry of 5.4% in 3 years.
• If Omada Health's profit margin were to converge on the industry average, you could expect earnings to reach $25.2 million (and earnings per share of $0.36) by about January 2029, up from $-26.2 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 60.3x on those 2029 earnings, up from -34.8x today. This future PE is greater than the current PE for the US Healthcare industry at 23.3x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Expanding GLP-1 prescribing and broader GLP-1 support could require sustained hiring and product build out, which may lift operating expenses faster than GLP-1 related revenue scales and put pressure on net margins and earnings.
• If employers or health plans change their GLP-1 coverage policies, slow approvals or look for cheaper alternatives, demand for Omada's GLP-1 Care Track and related services could soften, which may weigh on revenue growth and earnings visibility.
• Relying heavily on AI tools such as OmadaSpark, Meal Map and care team support software to improve efficiency carries execution risk, because if these tools do not keep member engagement high or fail to deliver the expected productivity gains, gross margin and net margins could stall.
• The multi-condition, B2B focused model depends on long enterprise selling cycles of 6 to 18 months. Any slowdown in closing new employer or payer deals, or weaker-than-expected pull through from channel partners, could slow membership additions and affect revenue and adjusted EBITDA.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Omada Health is $17.53, which represents up to two standard deviations below the consensus price target of $26.27. This valuation is based on what can be assumed as the expectations of Omada Health's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $17.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $471.0 million, earnings will come to $25.2 million, and it would be trading on a PE ratio of 60.3x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $15.74, the analyst price target of $17.53 is 10.2% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.